Published online October 31, 2008
PEDIATRICS Vol. 122 No. 5 November 2008, pp. 1153-1154 (doi:10.1542/peds.2008-2152)
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow An erratum has been published
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Anderson, E. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Anderson, E. J.
Related Collections
Right arrow Adolescent Medicine
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

LETTER TO THE EDITOR

Importance of On-time RotaTeq Vaccination and Long-term Active Surveillance

Evan J. Anderson, MD
Divisions of Infectious Diseases,
Departments of Pediatrics and Medicine,
Children's Memorial and Northwestern Memorial Hospitals,
Northwestern University Feinberg School of Medicine,
Chicago, IL 60614

The first 20% of the full text of this article appears below.

To the Editor.—

I read with great interest the article by Haber et al,1 who studied intussusception after implementation of RotaTeq vaccination by using the passive Vaccine Adverse Event Reporting System (VAERS) and the active Vaccine Safety Datalink (VSD) surveillance systems. Two important points bear mentioning.

First, data from this study should not be misconstrued to support RotaTeq administration outside the US Food and Drug Administration (FDA)–licensed window.2 Although debated, reanalysis of the RotaShield data suggests that much of the risk of intussusception occurred in patients receiving RotaShield late (eg, first dose at 4 or 6 months).3–5 Compliance . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?